Results 151 to 160 of about 119,167 (297)

Correlation Between Gut Microbiota, Metabolites, and Diabetic Complications: A Two‐Sample Mendelian Randomization Study

Medicine Advances, EarlyView.
Fang et al. demonstrate a significant causal relationship among gut microbiota, gut metabolites, and diabetic complications, highlighting a biological link underlying mechanisms of diabetic vascular diseases. These findings provide important implications for future therapeutic strategy and risk prediction.
Jiaxi Fang, Leilei Zhai, Chan Huang, Liqin Li, Yong Wang, Jiaojiao Fan, Wei Zhou   +6 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges

Cardiovascular Diabetology
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity.
Francisco Westermeier, Enrique Z. Fisman
doaj   +1 more source

Glucose and Several Mitogenic Agents Modulate the Glucagon-Like Peptide-2 Receptor Expression in Cultured Rat Astrocytes. [PDF]

J Alzheimers Dis Rep, 2022
Velázquez E, Le Baut Ayuso Y, Blázquez E, Ruiz-Albusac JM.   +3 more
europepmc   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

Microbiota Medicine Research, EarlyView.
ABSTRACT The growing recognition of the microbiome's role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai, Yisha Lin, Renyou Gan, Xiaotao Shen, Shin Young Park, Sunjae Lee, Qi Su   +6 more
wiley   +1 more source

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. [PDF]

BMC Gastroenterol, 2023
Skarbaliene J, Mathiesen JM, Larsen BD, Thorkildsen C, Petersen YM.   +4 more
europepmc   +1 more source

Influence of dietary intake and eating patterns on reactive hypoglycemic events in patients postesophagectomy: A prospective observational study using continuous glucose monitoring

Nutrition in Clinical Practice, EarlyView.
Abstract Background Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under‐researched.
Rachel O'Kelly, Elaine Quigley, Katie Byrne, Mistura A. Kareem, Niamh Ni Mhaoinigh, Paul Healy, Michelle Fanning, John V. Reynolds, Claire L. Donohoe, Suzanne L. Doyle   +9 more
wiley   +1 more source

Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells. [PDF]

Cell Mol Gastroenterol Hepatol, 2022
Chen ME, Naeini SM, Srikrishnaraj A, Drucker DJ, Fesler Z, Brubaker PL.   +5 more
europepmc   +1 more source

Glucagon-like peptide 2 and inflammatory bowel disease

, 2000
Bibliography: p.
openaire   +2 more sources

A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome

Nutrition in Clinical Practice, EarlyView.
Abstract Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited.
Tsuyoshi Sakurai, Hironori Kudo, Nakamura Megumi, Ryo Ando, Takuro Kazama, Ryuji Okubo, Masatoshi Hashimoto, Ko Minoshima, Motoshi Wada   +8 more
wiley   +1 more source

Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog. [PDF]

Physiol Res, 2022
Glerup P, Sonne K, Berner-Hansen M, Skarbaliene J.   +3 more
europepmc   +1 more source